Arvaya Healthcare Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Arvaya Healthcare Ltd trades at ₹116, in a confirmed uptrend and 53 weeks into that stage. That is +76.2% against its own 200-day average. It sits at 71% of a 52-week range of ₹58 to ₹139. On relative strength it has no relative-strength read yet.

Today the stock is in a confirmed uptrend — week 53 of stage 2, confirmed. At ₹116 it trades +76.2% versus its 200-day average and sits at 71% of its 52-week range (₹58–₹139).

Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +100% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Arvaya Healthcare Ltd trades at 419.0× P/E, against too little history to rank. Its long-run median P/E is 792.4×, measured across 0.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 419.0× is against too little history to rank, against a long-run median of 792.4× measured over 0.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Arvaya Healthcare Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Arvaya Healthcare Ltd reported ₹29.9 Cr of revenue in the Jun 26 quarter. Over 10 years it has compounded at 36.0% a year. The last full year, FY26, came in at ₹9.1 Cr. The last four reported quarters add to ₹39.0 Cr.

FY26 revenue came in at ₹9.1 Cr (+3,153.6% on the year), capping 10 years at 36.0% compound. The latest quarter (Jun 26) printed ₹29.9 Cr, null year on year.

Pace check: the last four quarters averaged −100.0% growth against the decade's 36.0% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +20,436.8% over the last 4 quarters against +1,040.5%/yr over the last 8 — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Arvaya Healthcare Ltd's operating margin is 13.2% in the Jun 26 quarter. That is the widest this company has ever printed on a full-year basis. Across 12 fiscal years the operating margin has ranged −182.1% to 7.9%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 13.2%, null pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −182.1%–7.9%, and FY26's 7.9% is the top of that band — a record year.

Why the margin moved: operating margin went +124.3 pp year on year while gross margin went +61.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Arvaya Healthcare Ltd earned ₹0.5 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹0.9 Cr. That is 1.8% of the quarter's revenue. The same quarter a year earlier lost ₹0.3 Cr. 9 of the last 12 reported quarters were loss-making.

Jun 26 profit was ₹0.5 Cr, null year on year. On the full year, FY26 printed ₹0.9 Cr (+542.9%).

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 2 fiscal years −294% of Arvaya Healthcare Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−3.3 Cr of operating cash against ₹0.9 Cr of profit. After ₹1.0 Cr of capital spending, ₹−4.0 Cr was left as free cash.

FY26: operating cash of ₹−3.3 Cr against reported profit of ₹0.9 Cr, leaving free cash of ₹−4.0 Cr after ₹1.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is −294% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at −294%: the cash cycle tightened 138 days between FY20 and FY25 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Arvaya Healthcare Ltd's cash conversion cycle runs 0 days in FY25, down from 138 days in FY20. Capital spending ran ₹1.0 Cr over the last 3 years. At FY26 sales of ₹9.1 Cr each day of that cycle holds about ₹0.0 Cr, so roughly ₹0.0 Cr sits inside the business at any moment.

FY25: debtors at 0 days, inventory at 0 days — roughly 0.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 0 days, tighter than FY20's 138.

In money terms: at FY26 sales of ₹9.1 Cr, each day of the cycle holds about ₹0.0 Cr — so the 0-day loop keeps roughly ₹0.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹1.0 Cr over the last 3 fiscal years against ₹1.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Arvaya Healthcare Ltd earns a ROCE of −4% in FY26. That is up from a trough of −12% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 9.9% net margin on 0.13× asset turns.

FY26 ROCE is −4%, recovered from a FY23 trough of −12% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 9.9% net margin × 0.13× asset turns × 1.18× balance-sheet leverage ≈ 1.5% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Arvaya Healthcare Ltd carries ₹2.5 Cr of borrowings against ₹58.0 Cr of equity in FY26, a debt-to-equity of 0.04. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹0.0 Cr to ₹2.5 Cr. Capital spending ran ₹1.0 Cr across the last 3 of those years.

FY26: borrowings of ₹2.5 Cr against equity of ₹58.0 Cr — a debt-to-equity of 0.04. Operating profit covers the interest bill 2×. Over 5 years borrowings went from ₹0.0 Cr to ₹2.5 Cr while capital spending ran ₹1.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters added 22.9 points of Arvaya Healthcare Ltd over 8 quarters, the biggest move on the register. That takes promoters to 30.6% of the company. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +22.9 points over 8 quarters to 30.6%.

Why the register moved: promoters drove it (+22.9 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Arvaya Healthcare Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions